This finding may be due to the benefit of ADT in patients with metastatic disease, and men with a presalvage PSA level of more than 1.5 ng/mL have a high probability of already harboring regional and distant metastatic disease. This evidence concerns the gene KLK3 and metastatic neoplasm.